Molecular Templates, Inc. (OTC:MTEM)
Industry: Biotechnology

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas. On April 20, 2025, Molecular Templates, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Current Quote*
Last: $0.000
Change: 0.000
Book: $0.372
Volume: 3,379

As Of: 07/02 16:09 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol MTEM

  • No BuyIns.Net Alerts Available for MTEM

Graphs for MTEM


3 Month Graph


6 Month Graph


1 Year Graph